On 2 December, the US POINTER study team shared topline results from 3 National Institutes of Health’s (NIH)-funded ancillary studies at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego (USA). The US POINTER is a clinical trial to evaluate whether lifestyle interventions that simultaneously target multiple risk factors protect cognitive function in older adults (age 60-79) at increased risk for cognitive decline. Participants were randomised to receive either a structured, coach-supported lifestyle program or a self-guided version. Presented results showed that a two-year structured lifestyle intervention with regular, structured support, which has already shown that it can improve cognition in adults at risk for cognitive decline, may also improve blood pressure regulation and reduce hourly sleep apnea respiratory events. A fourth study (POINTER-Microbiome) focused on the gut microbiome will report results at a later date.